Peter leads the Patient Operations function which is the primary point of contact within the CMC function at bluebird bio for Centers of Excellence (COE) interfaces including the collection of patient cells, manufacture of drug product, and operational execution of patient treatments. Creating an optimized point of care experience for patients, providers, and stakeholders related to the treatment process. Peter is also the program leader for LentiGlobin, which is being evaluated for patients with Transfusion Dependent Thalassemia (TDT). As the Program lead, he isesponsible for the Program team which is comprised of cross functional representatives spanning research, development, and commercial.